Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
AARDSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September:
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
AARDSAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided pipeline and business updates.
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
AARDSAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in the validated diet-induced obesity (DIO) mouse model (a conventional model recognized for its strong translational relevance in the field of glucagon-like peptide-1 receptor agonists (GLP-1RAs)) demonstrated potential applications for ARD-201, including for the attenuation of weight gain after withdrawal from GLP-1RA therapies, as a monotherapy for weight loss without GLP-1RA therapy, as well as for weight loss in combination with GLP-1RA therapy. Details of the study will be submitted for peer review publication.
RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $20
AARDAardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY
AARD12 Health Care Stocks Moving In Tuesday's Pre-Market Session
AARDWhy United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
AARD12 Health Care Stocks Moving In Wednesday's Intraday Session
AARDRBC Capital Reiterates Outperform on Aardvark Therapeutics, Maintains $21 Price Target
AARDCantor Fitzgerald Reiterates Overweight on Aardvark Therapeutics, Maintains $50 Price Target
AARDAardvark Therapeutics FY24 EPS ($5.15) Down From ($1.82) YoY
AARDB of A Securities Maintains Buy on Aardvark Therapeutics, Raises Price Target to $26
AARDRBC Capital Initiates Coverage On Aardvark Therapeutics with Outperform Rating, Announces Price Target of $21
AARDCantor Fitzgerald Initiates Coverage On Aardvark Therapeutics with Overweight Rating, Announces Price Target of $50
AARDThis Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
AARDMorgan Stanley Initiates Coverage On Aardvark Therapeutics with Overweight Rating, Announces Price Target of $29
AARDB of A Securities Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $22
AARDAardvark Therapeutics Shares Resume Trade
AARDAardvark Therapeutics Shares Halted On Circuit Breaker To The Downside
AARDAardvark Therapeutics Shares Open For Trade At $15.18/Share; IPO Priced At $16/Share On 5.89M Shares
AARDAardvark Therapeutics IPO Price Indicating $16/Share On 174,698 Shares; IPO Priced At $16/Share On 5.89M Shares
AARDAardvark Therapeutics IPO Price Indicating $16/Share On 92,97 Shares; IPO Priced At $16/Share On 5.89M Shares
AARDTrading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
AARDPreview: Aardvark Therapeutics, Inc Set To IPO Tomorrow
AARD